These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 9825575

  • 1. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload.
    Borgna-Pignatti C, Franchini M, Gandini G, Vassanelli A, De Gironcoli M, Aprili G.
    Haematologica; 1998 Sep; 83(9):788-90. PubMed ID: 9825575
    [Abstract] [Full Text] [Related]

  • 2. Recent acquisitions in the management of iron overload.
    Franchini M.
    Ann Hematol; 2005 Oct; 84(10):640-5. PubMed ID: 16025271
    [Abstract] [Full Text] [Related]

  • 3. Subcutaneous bolus injection of deferoxamine is an alternative method to subcutaneous continuous infusion.
    Yarali N, Fişgin T, Duru F, Kara A, Ecin N, Fitoz S, Erden I.
    J Pediatr Hematol Oncol; 2006 Jan; 28(1):11-6. PubMed ID: 16394886
    [Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload.
    Franchini M, Gandini G, de Gironcoli M, Vassanelli A, Borgna-Pignatti C, Aprili G.
    Blood; 2000 May 01; 95(9):2776-9. PubMed ID: 10779420
    [Abstract] [Full Text] [Related]

  • 5. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
    Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, Larbaa D, Dreyfus F, Beyne-Rauzy O, Chaury MP, Roy L, Cheze S, Morel P, Fenaux P, GFM (Groupe Francophone des Myélodysplasies).
    Leuk Res; 2010 Jul 01; 34(7):864-70. PubMed ID: 20129667
    [Abstract] [Full Text] [Related]

  • 6. Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome.
    Ambruso DR, Mahony BS, Githens JH, Rhoades ED.
    Am J Pediatr Hematol Oncol; 1982 Jul 01; 4(2):115-23. PubMed ID: 7114394
    [Abstract] [Full Text] [Related]

  • 7. Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study.
    Osborne RH, De Abreu Lourenço R, Dalton A, Houltram J, Dowton D, Joshua DE, Lindeman R, Ho PJ.
    Value Health; 2007 Jul 01; 10(6):451-6. PubMed ID: 17970927
    [Abstract] [Full Text] [Related]

  • 8. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
    Delforge M, Selleslag D, Triffet A, Mineur P, Bries G, Graux C, Trullemans F, MacDonald K, Abraham I, Pluymers W, Ravoet C.
    Ann Hematol; 2011 Jun 01; 90(6):655-66. PubMed ID: 21318574
    [Abstract] [Full Text] [Related]

  • 9. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
    Wali YA, Taqi A, Deghaidi A.
    Pediatr Hematol Oncol; 2004 Jun 01; 21(5):453-60. PubMed ID: 15205089
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease.
    Kalpatthi R, Peters B, Kane I, Holloman D, Rackoff E, Disco D, Jackson S, Laver JH, Abboud MR.
    Pediatr Blood Cancer; 2010 Dec 15; 55(7):1338-42. PubMed ID: 20981690
    [Abstract] [Full Text] [Related]

  • 11. Urinary iron excretion induced by intravenous infusion of deferoxamine in beta-thalassemia homozygous patients.
    Boturao-Neto E, Marcopito LF, Zago MA.
    Braz J Med Biol Res; 2002 Nov 15; 35(11):1319-28. PubMed ID: 12426631
    [Abstract] [Full Text] [Related]

  • 12. Concepts and goals in the management of transfusional iron overload.
    Porter JB.
    Am J Hematol; 2007 Dec 15; 82(12 Suppl):1136-9. PubMed ID: 17968973
    [Abstract] [Full Text] [Related]

  • 13. Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator.
    Harmatz P, Grady RW, Dragsten P, Vichinsky E, Giardina P, Madden J, Jeng M, Miller B, Hanson G, Hedlund B.
    Br J Haematol; 2007 Aug 15; 138(3):374-81. PubMed ID: 17614825
    [Abstract] [Full Text] [Related]

  • 14. Socio-psychological impact of infused iron chelation therapy with deferoxamine in metropolitan France: ISOSFER study results.
    Thuret I, Hacini M, Pégourié-Bandelier B, Gardembas-Pain M, Bisot-Locard S, Merlat-Guitard A, Bachir D.
    Hematology; 2009 Dec 15; 14(6):315-22. PubMed ID: 19941737
    [Abstract] [Full Text] [Related]

  • 15. Reassessment of the use of desferrioxamine B in iron overload.
    Propper RD, Shurin SB, Nathan DG.
    N Engl J Med; 1976 Jun 24; 294(26):1421-3. PubMed ID: 1272274
    [Abstract] [Full Text] [Related]

  • 16. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload.
    Schafer AI, Rabinowe S, Le Boff MS, Bridges K, Cheron RG, Dluhy R.
    Arch Intern Med; 1985 Jul 24; 145(7):1217-21. PubMed ID: 3925909
    [Abstract] [Full Text] [Related]

  • 17. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality.
    Takatoku M, Uchiyama T, Okamoto S, Kanakura Y, Sawada K, Tomonaga M, Nakao S, Nakahata T, Harada M, Murate T, Ozawa K, Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes.
    Eur J Haematol; 2007 Jun 24; 78(6):487-94. PubMed ID: 17391310
    [Abstract] [Full Text] [Related]

  • 18. Iron chelation therapy in MDS: does it improve survival?
    Leitch HA.
    Leuk Res; 2010 Jul 24; 34(7):852-3. PubMed ID: 20346508
    [No Abstract] [Full Text] [Related]

  • 19. Long-term administration of high-dose deferoxamine 2 days per week in thalassemic patients.
    Hagège I, Becker A, Kerdaffrec T, Kanfer A, Girot R.
    Eur J Haematol; 2001 Oct 24; 67(4):230-1. PubMed ID: 11860443
    [Abstract] [Full Text] [Related]

  • 20. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
    Gattermann N.
    Leuk Res; 2007 Dec 24; 31 Suppl 3():S10-5. PubMed ID: 18037413
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.